Marc Azemar
University of Freiburg
15 Papers
313 Citations
Marc Azemar is an academic researcher from University of Freiburg. The author has contributed to research in topics: Medicine & Immunotherapy. The author has an hindex of 10, co-authored 15 publications.
Chat about Author
Papers
Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera.
Snežana Temerinac,Steffen Klippel,Elisabeth Strunck,Sabine Röder,Michael Lübbert,Winand Lange,Marc Azemar,Gerold Meinhardt,Hans-Eckart Schaefer,Heike L. Pahl +9 more
TL;DR: It is proposed that PRV-1 represents a novel hematopoietic receptor in PV and is highly expressed in normal human bone marrow and to a much lesser degree in fetal liver, while it is not expressed in a variety of other tissues tested.
212
Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2.
Marc Azemar,S. Djahansouzi,Elke Jäger,Christine Solbach,Mathias Schmidt,Alexander B. Maurer,Klaus Mross,Clemens Unger,Gunter von Minckwitz,Peter Dall,Bernd Groner,Winfried S. Wels +11 more
TL;DR: It is demonstrated that local therapy with scFv(FRP5)-ETA can be effective against ErbB2 expressing tumors justifying further clinical development of this reagent.
102
Immunotherapy of patients with hormone‐refractory prostate carcinoma pre‐treated with interferon‐gamma and vaccinated with autologous PSA‐peptide loaded dendritic cells—A pilot study
Bernd Hildenbrand,B. Sauer,O. Kalis,C. Stoll,Marina A. Freudenberg,G. Niedermann,J.M. Giesler,E. Jüttner,J.H. Peters,B. Häring,R. Leo,Clemens Unger,Marc Azemar +12 more
TL;DR: A pilot trial to assess the feasibility and tolerability of a prime/boost vaccine strategy using interferon‐gamma (IFN‐γ) and autologous dendritic cells (DCs) pulsed with HLA‐A2‐specific prostate‐specific antigen (PSA) peptides for the treatment of 12 patients with hormone refractory prostate carcinoma.
49
Purging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins.
Alexandros Spyridonidis,M. Schmidt,W. Bernhardt,A. Papadimitriou,Marc Azemar,Winfried S. Wels,Bernd Groner,Reinhard Henschler +7 more
TL;DR: Rec recombinant immunotoxins directed against cell-surface antigens expressed on mammary carcinoma cells are highly efficient and convenient to use for the depletion of mammary tumor cells during ex vivo expansion of hematopoietic progenitor-cell autografts.
41
Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study
TL;DR: In this paper, the authors conducted a pilot trial to assess the tolerability, clinical benefit and antitumoral efficacy of modified (hydrolysed) citrus pectin (MCP) in 49 patients with various solid tumors in an advanced state of progression.
39